Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of IFM Therapeutics. The transaction includes full rights to IFM's preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
- Details
- Category: AstraZeneca
AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. Tezepelumab is a first-in-class anti-TSLP monoclonal antibody being developed by MedImmune, AstraZeneca’s global biologics research and development arm, in collaboration with Amgen.
Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer
- Details
- Category: Bristol-Myers Squibb
The first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride. Ninety-three novice riders will bike a total of nearly 2,800 miles during the 21-day mission to raise money and awareness for Stand Up To Cancer’s innovative cancer research programs that bring together collaborative teams of scientific researchers to help get new therapies to patients faster.
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira®
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including:
Abbott and the Abbott Fund donate $1 million to support Hurricane Harvey relief efforts
- Details
- Category: Abbott
Abbott (NYSE: ABT) and its foundation, the Abbott Fund, are providing $1 million in grants and healthcare and nutrition products to help deliver immediate relief following Hurricane Harvey and the devastating flooding affecting Texas and Louisiana. The Abbott Fund is providing $900,000 in grants to the American Red Cross, Americares and Direct Relief. Abbott is donating $100,000 in healthcare and nutrition products to relief organizations providing on-the-ground support in affected communities.
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019)
- Details
- Category: Novartis
First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2].
Novartis announced that the US Food and Drug Administration (FDA) has approved Kymriah(TM)(tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy,
Novartis announced that the US Food and Drug Administration (FDA) has approved Kymriah(TM)(tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy,
Merck collaborates with angiex to speed clinical readiness of new cancer therapy
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up's ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibodydrug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.
More Pharma News ...
- AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease
- Victoza® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
- Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
- Novartis appoints Bertrand Bodson as Chief Digital Officer
- Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
- Alliance Foundation Trials opens global trial investigating first-in-class palbociclib in HR+, HER2+ metastatic breast cancer
- Amgen and Humana partner for improved health outcomes and efficiency